

The Viceroy Study:
A Clinical Research Study in Adults with Newly Diagnosed Acute Myeloid Leukemia

VICEROY

Visit-by-Visit Scheduler

Welcome

Thank you for choosing to participate in the **Viceroy Study**. You are making a valuable contribution to medical research and helping us learn more about potential future treatment opportunities for adults **with acute myeloid leukemia (AML).**

During this study, you will be supported by a team of doctors, nurses and other healthcare professionals, who are dedicated to your well-being, which is our top priority. The commitment of each participant and the study team is important to help meet the objectives of this study.

This **visit-by-visit scheduler** includes information about each of your study visits, so you know what to expect at each visit.

If you have questions about any of the procedures or assessments described in this guide or about the **Viceroy Study** in general, please do not hesitate to ask a member of the study team.

Thank you for your participation in this clinical research study; we look forward to seeing you soon!

Glossary of Procedure and Assessment Icons

Review and sign informed consent form

Check eligibility to participate

Review medical history

Record vital signs
(your body temperature, pulse rate, respiratory rate and blood pressure will be measured)

Physical exam
(your head and neck, abdominal area, and breathing will be examined)

Review current and past medications

Participant assessment of health

Review any side effects

Measure height

Measure weight

Collect blood samples

Collect urine samples

Pregnancy test for women of childbearing potential

Take bone marrow sample
(a sample of your bone marrow will be extracted from your bones using a special needle)

Chest X-ray
(your heart, lungs, blood vessels, airways, and bones of the chest and spine will be scanned)

Electrocardiogram
(the electrical activity of your heart will be measured)

Administration of study drug gilteritinib

Administration of study drug venetoclax

Administration of study drug azacytidine

Study Visits

Throughout the **Viceroy Study**, you will be asked to **visit the study site** up to **54 times** over **3 years**.

Study visits will occur more often during the first 6 treatment cycles, and less often during any subsequent cycles. You may need to take time off work for study visits. Visit times may vary and you can ask the study team how long you should plan to be at the study center, for any given visit.

In addition to being given the study drugs (at some visits) you will also have some procedures and assessments at these visits. These will help to check on your health and well-being, and to determine how you are responding to the study drugs.

Here's an at-a-glance visit-by-visit scheduler of procedures and assessments:

Screening Visit

Day -28 to -1

Initial Treatment Period

Cycle 1 (Day 1)



*Days 1-7 of each cycle.

†Gilteritinib should be taken in the clinic on scheduled clinic days after laboratory assessment.

Cycle 1 (Day 2 to 7)

Cycle 1 (Day 8)



Cycle 1 (Day 14)

Cycle 1 (Day 21)

Cycle 1 (Day 28)

Cycles 2 to 3 (Day 1)



Cycles 2 to 3 (Day 8, 14 and 21)

Cycles 4 to 6 (Day 1)



Cycles 4 to 6 (Day 14)

Cycles 7 to 12 (Day 1)



Long-term Treatment Period

Cycles 1 to 24 (Day 1)

*And Day 1 of every 6 subsequent cycles and as needed.



End-of-Treatment

30-day Follow-up

Leaving the Study

You are free to withdraw from the **Viceroy Study** at any time and for any reason. If you withdraw, there will be no penalty or loss of benefits regarding your future health care. Your participation in the **Viceroy Study** may be stopped if:

- You experience an unexpected medical problem that means it is unsafe for you to continue.
- You become pregnant.
- You do not respond to the investigational combination of drugs, or your cancer gets worse.
- The study doctor decides that continuing in the study is not in your best interests.
- You do not follow instructions given to you by the study team.
- You take a drug that is prohibited while on the study.

If you have any questions about withdrawal or removal from the study, please contact the study team.

Reminders

The reminders below will help your participation in the **Viceroy Study** run as smoothly as possible:

- Keep your study visit appointments. If you are unable to attend, let the study team know immediately so that they can reschedule the visit.
- Tell your study doctor about any differences in how you feel, any new drugs you are taking, or any hospital visits attended.
- Tell your study doctor immediately if you experience worsening of your cancer symptoms or any side effects from the investigational combination of drugs.
- Do not take part in any other clinical research study. Tell your regular doctor that you are taking part in this study.

Thank You

Clinical research studies such as the **Viceroy Study** could not take place without you. Your participation in this study is helping us learn more about AML and potentially discover new ways of treating people with this condition.

Study Team Contact Information

Study site doctor name:

Study site coordinator name:

Study site coordinator email:

Study site name:

Study site address:

Study site telephone:

Study site opening hours:

After hours emergency study contact number: